Oral lichen planus: comparative efficacy and treatment costs-a systematic review.

Shaiba Sandhu, Brittany A Klein, Malak Al-Hadlaq, Prazwala Chirravur, Amal Bajonaid, Yuanming Xu, Rossella Intini, Mai Hussein, Piamkamon Vacharotayangul, Herve Sroussi, Nathaniel Treister, Stephen Sonis

Journal: BMC oral health 2022;22(1):161

PMID: 35524296

Abstract

OBJECTIVE

To compare the reported efficacy and costs of available interventions used for the management of oral lichen planus (OLP).

MATERIALS AND METHODS

A systematic literature search was performed from database inception until March 2021 in MEDLINE via PubMed and the Cochrane library following PRISMA guidelines. Only randomized controlled trials (RCT) comparing an active intervention with placebo or different active interventions for OLP management were considered.

RESULTS

Seventy (70) RCTs were included. The majority of evidence suggested efficacy of topical steroids (dexamethasone, clobetasol, fluocinonide, triamcinolone), topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporine), topical retinoids, intra-lesional triamcinolone, aloe-vera gel, photodynamic therapy, and low-level laser therapies for OLP management. Based on the estimated cost per month and evidence for efficacy and side-effects, topical steroids (fluocinonide > dexamethasone > clobetasol > triamcinolone) appear to be more cost-effective than topical calcineurin inhibitors (tacrolimus > pimecrolimus > cyclosporine) followed by intra-lesional triamcinolone.

CONCLUSION

Of common treatment regimens for OLP, topical steroids appear to be the most economical and efficacious option followed by topical calcineurin inhibitors. Large-scale multi-modality, prospective trials in which head-to-head comparisons interventions are compared are required to definitely assess the cost-effectiveness of OLP treatments.

© 2022. The Author(s).

Address: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston, USA. [email protected].; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, USA. [email protected].; Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. [email protected].; Division of Oral Medicine and Dentistry, Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston, USA.; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, USA.; Harvard Medical School, Boston, MA, USA.; Ministry of Health and Population, Cairo, Egypt.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.